![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, February 19, 2022 9:21:45 AM
He sold his shares.... big dip following day.
now the news you showed me was literally just a matter of time and I don't tell the future to say "hey" Friday we are getting good news.
Take that news away and see how what I said was true. You are messing with the wrong person I've been a long around here for a long time and hold a ton of shares. I haven't sold one and the reason is because I've been waiting on this news. Take that first half of my message and understand that I was correct on it.
also it sucks for the CEO because he sold the day before but OCGN was not the reason for the news it was the FDA itself saying they are allowing the studies in the USA. So OCGN just retweeted it or mentioned it in a news release. Shank could have made another few hundred grand but... he will in 3 months
He and a few others in the office do it every other 3 months if you don't believe me I will pull that data.
Recent OCGN News
- Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease • GlobeNewswire Inc. • 06/21/2024 11:00:00 AM
- Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 06/20/2024 10:30:31 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/18/2024 08:29:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:31:02 PM
- Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy • GlobeNewswire Inc. • 05/31/2024 12:36:49 PM
- Ocugen to Present at BIO International Convention 2024 • GlobeNewswire Inc. • 05/29/2024 11:15:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/28/2024 08:05:59 PM
- Ocugen Set to Join Russell 3000® Index Effective June 28, 2024 • GlobeNewswire Inc. • 05/28/2024 11:02:39 AM
- Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 • GlobeNewswire Inc. • 05/20/2024 11:00:52 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/17/2024 08:30:54 PM
- Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy • GlobeNewswire Inc. • 05/15/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 07:54:50 PM
- Ocugen Provides Business Update with First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 12:00:25 PM
- US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report • IH Market News • 05/14/2024 11:18:01 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:32:02 AM
- Form 8-A12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 05/10/2024 08:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:14:11 PM
- Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock • GlobeNewswire Inc. • 05/10/2024 08:05:06 PM
- Ocugen to Present at May 2024 Investor Conferences • GlobeNewswire Inc. • 05/10/2024 11:45:07 AM
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/03/2024 11:30:05 AM
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress • GlobeNewswire Inc. • 05/02/2024 11:15:46 AM
- Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 • GlobeNewswire Inc. • 04/29/2024 10:45:00 AM
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 01:05:24 PM
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 10:30:40 AM
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy • GlobeNewswire Inc. • 04/19/2024 11:13:05 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM